{
    "clinical_study": {
        "@rank": "105809", 
        "arm_group": {
            "arm_group_label": "NeMo Patch and NeMo Probe", 
            "arm_group_type": "Other", 
            "description": "TBI and SAH patients, one arm"
        }, 
        "brief_summary": {
            "textblock": "To assess the feasibility of a new neuromonitoring system (NeMoSystem including NeMo Probe\n      and NeMo Patch) and the accuracy of the measurement values (cerebral blood flow (CBF);\n      cerebral blood volume (CBV)) obtained."
        }, 
        "brief_title": "A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Subarachnoid Hemorrhage", 
            "Optical Imaging"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Subarachnoid Hemorrhage", 
                "Brain Injuries", 
                "Wounds and Injuries"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult male or female patient, \u2265 18 and \u2264 75 years\n\n          2. Patient with severe SAH (GCS \u2264 12) or severe TBI (GCS \u2264 8)\n\n          3. Decreased level of consciousness with the need for ICP monitoring for an estimated\n             duration of more than 3 days\n\n          4. Negative pre-treatment serum pregnancy test for female patients with childbearing\n             potential\n\n          5. In patients with severe SAH or severe TBI with need for ICP monitoring an acute\n             emergency situation exists. The inclusion follows\n\n        Exclusion Criteria:\n\n          1. Known kidney disease, defined as plasma creatinine > 120 \u00b5mol/l\n\n          2. Known liver disease, defined as GOT > 200U/l\n\n          3. History of allergic disorders, including allergic reactions against contrast agents\n             containing iodine, against ICG and against plasters, as well as patients with thyroid\n             disease causing hyperthyroidism\n\n          4. Pre-existing disability and/or legal representative\n\n          5. Participation in another interventional clinical trial within the last 30 days before\n             start of treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "83", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01802762", 
            "org_study_id": "CIV-AT-12-11-009203", 
            "secondary_id": "E!6526_OPTO-BRAIN"
        }, 
        "intervention": {
            "arm_group_label": "NeMo Patch and NeMo Probe", 
            "description": "A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)", 
            "intervention_name": "NeMo Patch and NeMo Probe", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 9, 2013", 
        "link": {
            "url": "http://www.nemodevices.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "gord.von-campe@medunigraz.at", 
                    "last_name": "Gord von Campe, MD", 
                    "phone": "+43-316-38581257"
                }, 
                "facility": {
                    "address": {
                        "city": "Graz", 
                        "country": "Austria", 
                        "zip": "8036"
                    }, 
                    "name": "Dept. of Neurosurgery, Medical University of Graz"
                }, 
                "investigator": {
                    "last_name": "Gord von Campe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "emanuela.keller@usz.ch", 
                    "last_name": "Emanuela Keller, MD", 
                    "phone": "+41442555671"
                }, 
                "facility": {
                    "address": {
                        "city": "Zurich", 
                        "country": "Switzerland", 
                        "zip": "8091"
                    }, 
                    "name": "Neurointensive Care Unit, University Hospital Zurich"
                }, 
                "investigator": {
                    "last_name": "Emanuela Keller, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Austria", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury", 
        "overall_contact": {
            "email": "emanuela.keller@nemodevices.ch", 
            "last_name": "Emanuela Keller", 
            "phone": "+41796025306"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Austria: Bundesamt f\u00fcr Sicherheit im Gesundheitswesen (BASG)", 
                "Switzerland: Swissmedic"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Feasibility:\nUser acceptance: For NeMo Probes in comparison to conventional probes for intracranial pressure (ICP-) monitoring; for NeMo Patch in comparison to patches for electroencephalography (EEG) monitoring.\nDetailled evaluation of user acceptance:\nIncidence of concerns of users in relation to the installation, function and removal of the NeMo System (= NeMo Probe, NeMo Patch, NeMo Control Unit and NeMo Software pre-installed on a Medical PC)\nUser-friendliness with a 3-graded scale (equal, better, worse) compared to conventional devices\nAccuracy of measurements:\n-Patients: Results from repeated measurements of mean transit time of ICG (mttICG), cerebral blood flow (CBF) and cerebral blood volume (CBV)\nSafety parameters:\nIncidence of complications (infections, brain tissue damage, haemorrhage) compared to historical series (patches for EEG and for BIS measurements; conventional probes for ICP monitoring)", 
            "measure": "To assess the feasibility of the neuromonitoring system and the accuracy of the measurement values.", 
            "safety_issue": "Yes", 
            "time_frame": "Day 28 after removal of medical device"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01802762"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Results concerning sensitivity and specificity to detect symptomatic vasospasm in  patients with subarachnoid hemorrhage (SAH) (correlation of events with CBF values < 15 ml/100g/min with defined criteria for vasospasm) Results concerning sensitivity and specificity to detect secondary infarctions and critical ICP values in TBI patients (correlation of events with CBF values < 15 ml/100g/min with defined criteria for secondary infarction) Results from repeated measurements for the difference between measurement values obtained with the NeMo Patch and the NeMo Probe, quantified with mathematical models", 
            "measure": "To demonstrate the ability of the neuromonitoring system to detect secondary ischemic events in patients with severe subarachnoid haemorrhage (SAH) or severe traumatic brain injury (TBI).", 
            "safety_issue": "No", 
            "time_frame": "Day 28 after removal of medical device"
        }, 
        "source": "NeMoDevices AG", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Medical University of Graz", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Zurich", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "NeMoDevices AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}